Harnessing AI for Precision Medicine: Transforming Care for Every Patient

Date: November 28, 2026 - November 28, 2026
Type: In-person
Location: Asia
Areas of Interest: Oncology

A strategic partnership to advance AI-enabled precision oncology.

28 November 2026 | 11:00 am | Amari Kuala Lumpur

About the event

Premier Integrated Labs (PIL) and SOPHiA GENETICS are entering a strategic partnership to bring AI-enabled precision oncology to patients. We invite clinicians, industry leaders and partners to witness the signing of the Memorandum of Understanding and to hear how genomic insights are being translated into clinical impact. Attendance is by invitation, with seating limited to 50 guests.

Programme

Time	Session
10:30 am	Registration and welcome reception
11:00 am	Opening address: En Hareeff Muhammad, Chief Executive Officer, PIL
11:05 am	Keynote: AI-Powered Precision Oncology: From Genomic Data to Clinical Impact. Dr Nicholas Tan, Managing Director, APAC, SOPHiA GENETICS
11:10 am	Corporate videos: PIL and SOPHiA GENETICS
11:20 am	Signing of the Memorandum of Understanding: Premier Integrated Labs × SOPHiA GENETICS
11:30 am	Refreshments and networking
12:15 pm	Clinical session: MSK-ACCESS®: Integrating Liquid Biopsy into Clinical Practice, followed by clinical cases on Precision Oncology in Practice: From Genomic Insights to Patient Care
TBC	Closing remarks

Speakers

En Hareeff Muhammad, Chief Executive Officer, Premier Integrated Labs
Dr Nicholas Tan, Managing Director, APAC, SOPHiA GENETICS

Venue and getting there

Amari Kuala Lumpur, 3, Jalan Bangsar, KL Eco City, 59200 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia.

Register Now

URL

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Company(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

3rd Party Opt-In

I agree that SOPHiA GENETICS may share my webinar registration details with 3rd parties, and that I may receive marketing communications from these 3rd parties. I understand that I can withdraw my consent at any time.

Job Title/Industry(Required)

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are those of the speakers and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services